MARKET

MESO

MESO

Mesoblast
NASDAQ
3.465
-0.165
-4.55%
Opening 10:19 05/30 EDT
OPEN
3.600
PREV CLOSE
3.630
HIGH
3.600
LOW
3.430
VOLUME
32.76K
TURNOVER
101.14K
52 WEEK HIGH
4.350
52 WEEK LOW
2.140
MARKET CAP
564.24M
P/E (TTM)
-5.9855
1D
5D
1M
3M
1Y
5Y
Chardan Capital Maintains Sell on Mesoblast, Lowers Price Target to $2
Benzinga · 5h ago
Mesoblast: Notice of Effectiveness
Press release · 5h ago
--Chardan Cuts Price Target on Mesoblast to $2 From $2.50 Reflecting Increased Share Count Dilution, Reiterates Sell Rating
--Chardan Cuts Price Target on Mesoblast to $2 From $2.50 Reflecting Increased Share Count Dilution, Reiterates Sell Rating
MT Newswires · 8h ago
Mesoblast: Report of foreign issuer
Press release · 4d ago
Mesoblast Q3 EPS $(0.03) Beats $(0.17) Estimate, Sales $1.94M Miss $2.14M Estimate
Benzinga · 4d ago
Mesoblast GAAP EPS of -$0.025 beats by $0.13, revenue of $1.94M misses by $0.18M
Seeking Alpha · 4d ago
Mesoblast: Registration statement for specified transactions by certain foreign private issuers
Press release · 05/18 06:08
Mesoblast Has A Strong Upside Potential
Seeking Alpha · 05/04 20:22
More
About MESO
Mesoblast Limited is an Australia-based company that is engaged in the development of regenerative medicine products. The Company’s primary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It has applied its mesenchymal lineage cell technology platform to the allogeneic cellular medicines portfolio in the industry. Its technology addresses multiple inflammatory conditions with unmet medical needs. The Company’s portfolio of Phase III product candidates comprises remestemcel-L for steroid-refractory acute graft versus host disease (acute GVHD), as well as for the treatment of moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection, Revascor for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. The Company’s subsidiaries include Mesoblast, Inc., Mesoblast International Sarl, Mesoblast Australia Pty Ltd, Mesoblast UK Ltd and BeiCell Ltd.

Webull offers kinds of Mesoblast Ltd (ADR) stock information, including NASDAQ:MESO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MESO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MESO stock methods without spending real money on the virtual paper trading platform.